Agilent Technologies, Inc.
1.87 %
-13.86 %
Yet to be announced
Company Overview
Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise. Agilent focuses on six key market segments: Food, Environmental & Forensics, Pharmaceutical, Diagnostics, Chemical & Energy, and Research.
The company's main business involves developing and manufacturing analytical instruments, software, services and consumables for laboratories. Their products enable customers to gain the insights they need in areas such as food safety, environmental quality, pharmaceutical development, and scientific research.
Revenue Sources
PassBased on a detailed review of Agilent's business segments and revenue sources, the company's primary income streams come from the sale of analytical instruments, software, services, and consumables to laboratories and research facilities. These products and services are used in legitimate scientific research and quality control applications. There is no evidence of revenue from prohibited sources exceeding the 2.5% threshold.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Jan. 31, 2025 | $1.68b | $1.33b | - | $28.0m | 0.00% | 2.10% |
| Oct. 31, 2024 | $1.7b | $1.32b | - | $32.0m | 0.00% | 2.42% |
| July 31, 2024 | $1.58b | $1.27b | - | $22.0m | 0.00% | 1.74% |
| April 30, 2024 | $1.57b | $1.23b | - | $20.0m | 0.00% | 1.63% |
Analysis of the last four quarters shows interest expenses ranging from $20-32 million per quarter against total expenses ranging from $1.23-1.33 billion. The interest expense to total expense ratios consistently remain well below 5% of total expenses, indicating interest is not material to the company's operations.
Operational Ethics
PassWhile Agilent maintains operations in various global markets, including China, there is no clear evidence of material ongoing collaboration with the Chinese Communist Party or other entities involved in human rights violations. The company's presence in these markets appears to be primarily commercial in nature, focused on providing scientific and analytical equipment to laboratories and research facilities.
Login to join the discussion